Skip to main content
Premium Trial:

Request an Annual Quote

The Next Bubble?

One of the next bubbles to hit may be genomics, says Alex Planes at The Motley Fool. The field is growing quickly, Planes notes, with more and more companies coming online and treatments and diagnostics starting to make their way to market — all driven by the steep decline of sequencing costs. "It's too early to tell just which sequencing companies will float on top of the genomics bubble, but if history is any guide, big growth will come after costs drop into routine-procedure territory," Planes says. "Perhaps after mid-decade, if this chart proves correct."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.